Dyne Therapeutics (DYN)
(Real Time Quote from BATS)
$12.60 USD
-0.46 (-3.52%)
Updated Oct 6, 2025 03:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DYN 12.60 -0.46(-3.52%)
Will DYN be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for DYN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DYN
Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect?
After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN)
DYN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround
Other News for DYN
Is DYN positioned for a breakout? Crossed Above 20 Day Moving Average shows up after climbing 4.06%
Is DYN getting ready to pop? NR7 shows up after rising 0.4%
Dyne Therapeutics' Valuation Leaves No Room For Error
DYN forms 200 Day Moving Average Resistance on October 1
Dyne Therapeutics Elects Brian Posner to Board